表皮生长因子受体D761Y突变及酪氨酸激酶抑制剂的作用 - Suppr

Suppr

超能文献

The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.

作者信息

Toyooka Shinichi, Date Hiroshi, Uchida Akiko, Kiura Katsuyuki, Takata Minoru

出版信息

Clin Cancer Res. 2007 Jun 1;13(11):3431; author reply 3431-2. doi: 10.1158/1078-0432.CCR-07-0070.

DOI:10.1158/1078-0432.CCR-07-0070

PMID:17545553

Abstract

摘要

相似文献

The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.表皮生长因子受体D761Y突变及酪氨酸激酶抑制剂的作用

Clin Cancer Res. 2007 Jun 1;13(11):3431; author reply 3431-2. doi: 10.1158/1078-0432.CCR-07-0070.

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.对吉非替尼耐药但对克唑替尼敏感的肺腺癌患者，同时存在表皮生长因子受体罕见突变（L861Q）以及ALK/MET/ROS1基因拷贝数增加。

J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37.

Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?不同的小分子酪氨酸激酶抑制剂能否克服对表皮生长因子受体酪氨酸激酶抑制剂的获得性耐药？

J Clin Oncol. 2007 Jun 20;25(18):2504-5. doi: 10.1200/JCO.2007.11.3258.

Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.在肺腺癌中对吉非替尼敏感的常见表皮生长因子受体（EGFR）突变，在人类恶性间皮瘤中并不常见。

Int J Cancer. 2006 Jan 15;118(2):521-2. doi: 10.1002/ijc.21271.

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.表皮生长因子受体突变型肺腺癌中对激酶抑制剂产生获得性耐药的新型D761Y和常见继发性T790M突变

Clin Cancer Res. 2006 Nov 1;12(21):6494-501. doi: 10.1158/1078-0432.CCR-06-1570.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的获得性耐药

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30.

The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.间歇性与持续性暴露于表皮生长因子受体（EGFR）酪氨酸激酶抑制剂对携带激活型EGFR突变的肺癌细胞系中EGFR T790M突变耐药克隆选择的影响

Oncotarget. 2016 Jul 12;7(28):43315-43323. doi: 10.18632/oncotarget.9703.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

Targeting targeted therapy.靶向靶向治疗。

N Engl J Med. 2004 May 20;350(21):2191-3. doi: 10.1056/NEJMe048101. Epub 2004 Apr 29.

Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.表皮生长因子受体突变型肺癌中，MET 激酶抑制剂 E7050 逆转了肝细胞生长因子诱导的酪氨酸激酶抑制剂耐药的三种不同机制。

Clin Cancer Res. 2012 Mar 15;18(6):1663-71. doi: 10.1158/1078-0432.CCR-11-1171. Epub 2012 Feb 8.

引用本文的文献

Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives.了解非小细胞肺癌对靶向治疗的反应及耐药性：临床见解与展望

Front Oncol. 2024 Jul 11;14:1387345. doi: 10.3389/fonc.2024.1387345. eCollection 2024.

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.表皮生长因子受体表达与非小细胞肺癌靶向治疗耐药模式：综述。

Cells. 2021 May 14;10(5):1206. doi: 10.3390/cells10051206.

Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation.一名携带罕见EGFR L858R/D761Y复合突变的中国转移性肺腺癌患者对奥希替尼的持久反应

Onco Targets Ther. 2020 Oct 14;13:10447-10451. doi: 10.2147/OTT.S268593. eCollection 2020.

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.获得性耐药的机制对第一代和第二代 EGFR 酪氨酸激酶抑制剂。

Ann Oncol. 2018 Jan 1;29(suppl_1):i10-i19. doi: 10.1093/annonc/mdx703.

Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high-grade neuroendocrine carcinoma.从携带有 EGFR 突变的原发性肺腺癌到高级别神经内分泌癌的组织学演变。

Thorac Cancer. 2018 Jan;9(1):129-135. doi: 10.1111/1759-7714.12549. Epub 2017 Nov 9.

Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer.信号重新布线的贝叶斯模型揭示了乳腺癌获得性耐药中基因失调的机制。

PLoS One. 2017 Mar 13;12(3):e0173331. doi: 10.1371/journal.pone.0173331. eCollection 2017.

[Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance  in Lung Cancer].[肺癌中表皮生长因子受体酪氨酸激酶抑制剂治疗及耐药中自噬的研究进展]

Zhongguo Fei Ai Za Zhi. 2016 Sep 20;19(9):607-14. doi: 10.3779/j.issn.1009-3419.2016.09.09.

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.肺腺癌患者对不可逆表皮生长因子受体酪氨酸激酶抑制剂阿法替尼获得性耐药的机制。

Oncotarget. 2016 Mar 15;7(11):12404-13. doi: 10.18632/oncotarget.7189.

Mechanisms of resistance to EGFR tyrosine kinase inhibitors.表皮生长因子受体酪氨酸激酶抑制剂的耐药机制。

Acta Pharm Sin B. 2015 Sep;5(5):390-401. doi: 10.1016/j.apsb.2015.07.001. Epub 2015 Jul 26.

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.非小细胞肺癌中表皮生长因子受体通路依赖性获得性表皮生长因子受体酪氨酸激酶抑制剂耐药。

Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验